Intellia Therapeutics
NTLA
290 hedge funds and large institutions have $2.93B invested in Intellia Therapeutics in 2023 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 107 increasing their positions, 91 reducing their positions, and 47 closing their positions.
51% more call options, than puts
Call options by funds: $18.7M | Put options by funds: $12.4M
18% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 91
9% more capital invested
Capital invested by funds: $2.69B → $2.93B (+$235M)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
2.1% less ownership
Funds ownership: 91.54% → 89.45% (-2.1%)
4% less funds holding
Funds holding: 303 → 290 (-13)
28% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$38.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$38.1M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$25.6M |
| 4 |
RCMU
Rokos Capital Management (UK)
London,
United Kingdom
|
+$22.1M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$47.7M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$18.6M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$17.7M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$17.4M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$15.5M |
NTLA Hedge Fund Activity: Q1 2023 in Review
290 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q1 2023, worth a combined $2.93B — up 8.7% from $2.69B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of NTLA and 34 opened new positions — a net loss of 13 holders — while 91 trimmed existing stakes and 107 added.
The largest buyer was Casdin Capital, adding an estimated $38.4M. The largest seller was Fidelity Investments, cutting an estimated $47.7M.
- 290 institutional investors held Intellia Therapeutics (NTLA) as of Q1 2023, down from 303 in Q4 2022.
- Funds reported $2.93B of Intellia Therapeutics stock for Q1 2023, up 8.7% quarter-over-quarter.
- 34 funds opened new Intellia Therapeutics positions in Q1 2023 and 47 closed out, a net change of -13 holders.
- The largest Intellia Therapeutics buyer in Q1 2023 was Casdin Capital, an estimated $38.4M added.
- The largest Intellia Therapeutics seller in Q1 2023 was Fidelity Investments, an estimated $47.7M sold.
Based on aggregated 13F filings for Q1 2023.